(Q33396522)

English

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Anne W Beaven

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas C Shea

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dominic T Moore

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tatyana Feldman

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anastasia Ivanova

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Madlyn Ferraro

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peggy Ford

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Judith Smith

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andre Goy

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

19 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

254-258

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.608445

21 January 2018

Identifiers

10.3109/10428194.2011.608445

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33396522&oldid=1610205631"